Global CAR-T Therapy Market Report 2020: Market is Expected to Stabilize and Reach $3,150 Million in 2025 - COVID-19 Impact and Recovery Forecast to 2030

News provided by

Feb 01, 2021, 06:00 ET

DUBLIN, Feb. 1, 2021 /PRNewswire/ -- The "CAR-T Therapy Global Market Opportunities and Strategies to 2030: COVID-19 Impact and Recovery" report has been added to ResearchAndMarkets.com's offering.

The global CAR-T therapy market reached a value of nearly $734.0 million in 2019. The market is expected to grow from $734.0 million in 2019 to $2,250 million in 2023 at a rate of 32.3%. The growth is mainly due to an increased prevalence of cancer and increased awareness about the therapy. The market is expected to stabilize and reach $3,150 million in 2025 and $6,100 million in 2030.

The CAR-T therapy market consists of sales of CAR-T therapy products and related services by entities (organizations, sole traders and partnerships) that develop chimeric antigen receptor (CAR) T-cell therapies to treat all types of cancers. This industry includes establishments that are involved in the research and development to introduce new targeted cell therapies for treating different blood related cancers.

Growth in the historic period resulted from increases in healthcare expenditure, increase in pharmaceutical R&D expenditure and advances in drug discovery. This growth was restricted by low rate of drug approvals, challenges due to regulatory changes and limited number of treatment centers.

Going forward, increase in blood cancer incidence rate, rise in healthcare expenditure, strong pipeline of drugs and rising focus on car-t therapy are expected to drive the market. High costs of therapy, reimbursement challenges, adverse events, complex manufacturing and supply chain and COVID-19 impacting drug trails, and reduction in free trade are major factors that could hinder the growth of the CAR-T therapy market in the future.

The CAR-T therapy market is segmented by target antigen into CD19, CD22, BCMA and others. The CD19 was the largest segment of the CAR-T therapy market by target antigen, accounting for 100% of the total market in 2019. Going forward, CD19 segment is expected to be the fastest growing segment in the CAR-T therapy market, at a CAGR of 25.3%.

The CAR-T therapy market is also segmented by application into acute lymphoblastic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, multiple myeloma and others. The diffuse large B-cell lymphoma was the largest segment of the CAR-T therapy market by application, accounting for 56.1% of the total market in 2019. Going forward, the others segment is expected to be the fastest growing segment in the CAR-T therapy market, at a CAGR of 29.3%.

North America was the largest region in the global CAR-T therapy market, accounting for 60.3% of the total in 2019. It was followed by Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the CAR-T therapy market will be Asia Pacific and Western Europe, where growth will be at CAGRs of 85.1% and 32.4% respectively.

The CAR-T therapy market is particularly prone to disruption from the coronavirus outbreak, as patients with cancer are more susceptible to viral infections, especially after chemotherapy, stem cell transplants, or surgeries. COVID-19 has caused clinical trial delays for CAR-T therapy drugs. Due to worldwide lockdown, production is also being halted which is causing supply chain issues.

The CAR-T therapy market is concentrated, with a small number of large of large players in the market. Major players in the market include Novartis AG and Gilhead Pharmaceuticals.

The top opportunities in the CAR-T therapy market segmented by target antigen will arise in the CD19 segment, which will gain $1,077.3 million of global annual sales by 2023. The top opportunities in the CAR-T therapy market segmented by application will arise in the diffuse large B-cell lymphoma segment, which will gain $738.5 million of global annual sales by 2023. The CAR-T therapy market size will gain the most in the USA at $744.9 million.

Market-trend-based strategies for the CAR-T therapy market include focus efforts towards investing in the R&D for creating remodeled CAR-T therapy to avoid neurological side-effects, creating off-the-shelf allogeneic CAR-T therapy for advanced cancer treatment, manufacturing next-generation CAR T cells for improved treatment of high-grade glioma, investing in AI and machine learning solutions to optimize future CAR-T therapy, carrying out strategic collaborations to boost innovations, collaborating or acquiring competitor companies to expand CAR-T therapy portfolio, and investing in the CAR-T therapy to make it more effective. Player-adopted strategies in the CAR-T therapy market include expansion through mergers and acquisitions, and strategic partnerships with technology companies.

To take advantage of the opportunities, the publisher recommends the CAR-T therapy companies should consider collaborating or acquiring competitor companies, invest in machine learning and artificial intelligence, next-generation car-t cells, competitive pricing, expanding in emerging markets, set up authorized distributors and sales representatives, leverage e-commerce to maximize reach and revenues, increasing adoption of internet, attending business events, targeting community oncologists/hematologists, and collaboration with treatment centers.

Key Topics Covered:

1. CAR-T Therapy Market Executive Summary

2. Table of Contents

3. List of Figures

4. List of Tables

5. Report Structure

6. Introduction
6.1.1. Segmentation by Geography
6.1.2. Segmentation by Application
6.1.3. Segmentation by Target Antigen

7. CAR-T Therapy Market Characteristics
7.1. Market Definition
7.2. Market Segmentation by Target Antigen
7.2.1. CD19 Therapy
7.2.2. CD22 Therapy
7.2.3. BCMA Therapy
7.2.4. Others
7.3. Market Segmentation by Application
7.3.1. Acute Lymphoblastic Leukemia
7.3.2. Diffuse Large B-Cell Lymphoma
7.3.3. Follicular Lymphoma
7.3.4. Chronic Lymphocytic Leukemia
7.3.5. Multiple Myeloma
7.3.6. Others

8. CAR-T Therapy Market Customer Information
8.1. Interest of Physicians
8.2. Positive Perception of Community Oncologists Towards CAR-T Therapy
8.3. Challenges and Perceived Barriers in the Adoption of CAR-T Therapy by Community Oncologists
8.4. Improvement in Quality of Life After CAR T-Cell Therapy

9. CAR-T Therapy Market Trends and Strategies
9.1. Remodeled CAR-T Cell Therapy for Fewer Side Effects
9.2. Off-The-Shelf Allogeneic CAR-T Therapy for Improved Treatment
9.3. Next-Generation CAR-T Cells for Treatment of High-Grade Glioma
9.4. Machine Learning and Artificial Intelligence to Optimize Future CAR-T Therapy
9.5. Collaborating with Technology Companies for Advanced Technologies
9.6. Growing Partnerships for Promoting CAR-T Therapy Market

10. CAR-T Therapy Market, COVID Impact Analysis
10.1. Impact on Global CAR-T Therapy
10.2. Impact on Global CAR-T Therapy Clinical Trials
10.3. Impact on Leading Global Oncology Companies

11. Global CAR-T Therapy Market Size and Growth
11.1. Historic Market Growth, 2015 - 2019, Value ($ Million)
11.1.1. Drivers of the Market 2015 - 2019
11.1.2. Restraints on the Market 2015 - 2019
11.2. Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
11.2.1. Drivers of the Market 2019 - 2023
11.2.2. Restraints on the Market 2019 - 2023

12. Global CAR-T Therapy Market Segmentation
12.1. Global CAR-T Therapy Market, Segmentation by Application, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
12.1.1. Diffuse Large B-Cell Lymphoma
12.1.2. Acute Lymphoblastic Leukemia
12.1.3. Follicular Lymphoma
12.1.4. Multiple Myeloma
12.1.5. Chronic Lymphocytic Leukemia
12.1.6. Others
12.2. Global CAR-T Therapy Market, Segmentation by Target Antigen, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
12.2.1. CD19
12.2.2. BCMA
12.2.3. Other Target Antigen
12.2.4. CD22

13. CAR-T Therapy Market, Regional and Country Analysis
13.1. Global CAR-T Therapy Market, by Region, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
13.2. Global CAR-T Therapy Market, by Country, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)

Companies Mentioned

Adaptimmune
Aeon Therapeutics
Astellas Pharma
AstraZeneca Holding GmbH
Autolus Therapeutics
Biocon
BioNTech
CARsgen Therapeutics
Celegne
Cellectis
Celyad
Crescendo Biologics
Daiichi Sankyo
Eli Lilly and Company
GammaDelta Therapeutics
Gilead Sciences
Gracell Biotechnology Ltd
Hebei Senlang Biotech
Immatics
Innovative Cellular Therapeutics Cellular Biomedicine Group
Japan Tissue Engineering
Johnson & Johnson Private Limited
MSD Laboratories India LLC
Nipro Corporation
Novartis AG
Ono Pharmaceutical
Otsuka Pharmaceutical
PersonGen Biomedicine
Takeda Pharmaceutical Company

For more information about this report visit https://www.researchandmarkets.com/r/lcpze7

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets